Madrigal Pharmaceuticals, Inc.

MDGL

US5588681057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:04:17 2026-01-15 EST			5-day change	1st Jan Change
504.04 ^USD	-0.23%		-9.75%	-13.80%

01-13	Madrigal Pharmaceuticals Insider Sold Shares Worth $9,617,312, According to a Recent SEC Filing	MT
01-12	Madrigal Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM

Madrigal expands its mash pipeline with exclusive global license agreement for ervogastat

Published on 01/09/2026 at 09:02 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Madrigal Pharmaceuticals, Inc.

01-13	Madrigal Pharmaceuticals Insider Sold Shares Worth $9,617,312, According to a Recent SEC Filing	MT
01-12	Madrigal Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM
01-09	Madrigal Pharmaceuticals, Inc. Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor	CI
01-09	Madrigal expands its mash pipeline with exclusive global license agreement for ervogastat	RE
01-09	Madrigal Pharmaceuticals Granted Worldwide Exclusivity for Pfizer Liver Disease Drug	MT
12-19	Altimmune's liver disease drug shows benefits in study, but investors remain unimpressed	RE
12-11	Madrigal Pharmaceuticals, Inc. Appoints Rita Thakkar as Senior Vice President and Chief Accounting Officer, Effective January 12, 2026	CI
12-11	B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating	MT
12-04	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing	MT
12-04	Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash	CI
12-04	Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals	RE
12-03	Madrigal Pharmaceuticals Insider Sold Shares Worth $2,413,416, According to a Recent SEC Filing	MT
11-21	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,082,986, According to a Recent SEC Filing	MT
11-20	Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4)	RE
11-20	Madrigal Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 08:30 AM
11-20	Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating	MT
11-19	Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating	MT
11-10	Madrigal Pharmaceuticals, Inc. Presents New Data Demonstrating Rezdiffra®? Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated Mash Cirrhosis	CI
11-05	Sector Update: Health Care Stocks Advance Late Afternoon	MT
11-05	Sector Update: Health Care	MT
11-05	Madrigal Pharmaceuticals Shares Rise After Cantor Fitzgerald Upgrade	MT
11-05	Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals to Overweight From Neutral	MT
11-04	Madrigal Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 04, 2025
11-04	Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-04	Madrigal Pharmaceuticals Q3 Net Loss Widens, Revenue Rises	MT

Chart Madrigal Pharmaceuticals, Inc.

Duration

Period

MDGL: Dynamic Chart

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Employees

528

Sector

Biotechnology & Medical Research

Calendar

03-03 - Q4 2025 Earnings Release (Projected)

More about the company